Can you take creatine on retatrutide? It is a question increasingly asked by individuals seeking to preserve muscle mass during significant weight loss. Retatrutide is an investigational triple incretin receptor agonist not yet approved by the MHRA or EMA for use in the UK, meaning its use outside regulated clinical trials is unlawful. Creatine, by contrast, is a well-researched, widely available supplement with an established safety record in healthy adults. This article examines how the two interact theoretically, what the current evidence says, and the key safety considerations you should discuss with a qualified healthcare professional.

How Retatrutide Works and Its Current Status in the UK

Retatrutide is an investigational triple incretin receptor agonist (GLP-1, GIP, and glucagon) that has not received MHRA or EMA approval; its use outside regulated clinical trials in the UK is unlawful and potentially unsafe.

Retatrutide is an investigational medicine currently undergoing clinical trials and has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the United Kingdom. It is therefore not legally available as a prescribed or over-the-counter medicine in the UK. Supply or sale of retatrutide outside of regulated clinical trials is unlawful and carries significant risks, including exposure to counterfeit or incorrectly dosed products. Anyone considering retatrutide should only do so within a regulated clinical trial and under appropriate medical supervision.

Pharmacologically, retatrutide is a triple incretin receptor agonist under investigation for its potential to activate three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism is intended to promote reductions in body weight and improve glycaemic control, though the full extent of these effects in humans is still being established in clinical trials. It is distinct from approved agents such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), which act on one or two of these pathways.

Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 (Jastreboff et al.) reported promising weight-loss outcomes, with some participants losing over 20% of body weight. However, the drug's complete safety profile, long-term effects, and drug interaction data remain under investigation. Until retatrutide receives formal regulatory approval and is prescribed within a supervised clinical framework, its use outside of trials is unapproved and potentially unsafe. Anyone considering it should consult a qualified healthcare professional.

What Creatine Is and Why People Use It

Creatine is a naturally occurring compound stored in muscle as phosphocreatine, widely used to improve strength, power, and muscle hypertrophy; the EFSA considers 3 g daily safe for long-term use in healthy adults.

Creatine is a naturally occurring compound synthesised in the body from the amino acids arginine, glycine, and methionine, primarily in the liver and kidneys. It is also obtained through dietary sources, particularly red meat and fish. Once synthesised or ingested, creatine is transported to skeletal muscle where it is stored as phosphocreatine. It is not hepatically metabolised in the conventional pharmacological sense; rather, it undergoes non-enzymatic conversion to creatinine, which is then excreted by the kidneys. In muscle, phosphocreatine plays a central role in the rapid regeneration of adenosine triphosphate (ATP) — the primary energy currency of cells — during short bursts of high-intensity physical activity.

Creatine monohydrate is one of the most extensively researched sports supplements available. According to the International Society of Sports Nutrition (ISSN) position stand, it is commonly used by athletes, bodybuilders, and recreational gym-goers to:

• Improve strength and power output during resistance training

• Support muscle hypertrophy (growth) over time

• Enhance recovery between high-intensity exercise bouts

• Potentially support cognitive function, though evidence in this area remains preliminary and inconclusive

The European Food Safety Authority (EFSA) has assessed creatine supplementation and considers a daily intake of 3 g safe for long-term use in healthy adults. Typical maintenance doses used in sports nutrition range from 3–5 g per day. Creatine is not a controlled substance in the UK and is widely available in health food shops and online retailers. When purchasing creatine, choosing products that carry third-party quality assurance (for example, Informed-Sport certification) reduces the risk of contamination with undeclared substances.

Despite its widespread use, creatine is not without considerations. It can cause water retention within muscle cells, leading to modest short-term weight gain. Higher doses or a loading phase (typically 20 g per day in divided doses for 5–7 days) may cause gastrointestinal discomfort; splitting doses and taking them with food can help minimise this. Maintaining adequate hydration is also advisable. Individuals with pre-existing kidney disease should consult a doctor before use, as creatine supplementation increases creatinine production and excretion, which can affect the interpretation of renal function tests — though this does not necessarily indicate a reduction in true kidney function in healthy individuals.

Potential Interactions Between Creatine and Retatrutide

No established clinical interaction between creatine and retatrutide exists; theoretical concerns include compounded gastrointestinal discomfort and artefactual serum creatinine rises that may complicate renal monitoring.

Because retatrutide has not yet received regulatory approval and its full pharmacological profile is still under investigation, there is currently no official, peer-reviewed evidence documenting a direct drug interaction between retatrutide and creatine. It is important to state clearly that there is no established clinical interaction between the two at this time, based on available data.

However, several theoretical considerations are worth noting:

• Renal considerations: Creatine supplementation increases creatinine production and excretion. This can cause a modest, artefactual rise in serum creatinine without any true reduction in kidney function (glomerular filtration rate). This is important to bear in mind when interpreting renal blood tests in anyone taking creatine, particularly if renal monitoring is being undertaken. Individuals with pre-existing kidney disease should seek medical advice before combining creatine with any potent weight-loss agent.

• Gastrointestinal effects: GLP-1 receptor agonists as a class are well known to cause nausea, vomiting, and delayed gastric emptying. Creatine supplementation, particularly at higher doses or during a loading phase, can also cause gastrointestinal discomfort. Taking both simultaneously may theoretically compound these symptoms. Using lower, divided creatine doses and taking them with food may help.

• Fluid balance: Creatine promotes intracellular water retention in muscle. The net effect on overall hydration when combined with retatrutide has not been formally studied. Maintaining adequate fluid intake is advisable.

Given the absence of formal interaction data, it would be premature to declare the combination either safe or unsafe. Anyone using retatrutide — particularly outside of a supervised clinical trial — should disclose all supplements, including creatine, to their prescribing clinician or pharmacist to enable an individualised risk assessment.

Muscle Mass, Weight Loss, and the Role of Creatine

Creatine supplementation combined with resistance exercise has a well-evidenced role in attenuating muscle loss during significant weight reduction, making its use physiologically plausible alongside potent weight-loss agents such as retatrutide.

One of the most clinically relevant reasons individuals ask about combining creatine with retatrutide relates to the preservation of lean muscle mass during significant weight loss. Rapid or substantial weight reduction — such as that observed in trials of retatrutide — is associated with loss of both fat mass and lean body mass, including skeletal muscle. This is a recognised concern with all potent weight-loss interventions.

Creatine supplementation has a well-established evidence base for supporting muscle mass and strength, particularly when combined with resistance exercise. Systematic reviews and meta-analyses (including those cited in the ISSN position stand) have demonstrated that creatine supplementation, alongside structured resistance training, can help attenuate reductions in muscle mass and strength. Evidence specifically examining creatine during pharmacologically assisted weight loss is limited, but the physiological rationale for its use in this context is scientifically plausible.

From a practical standpoint, individuals using GLP-1-based therapies (the approved class most pharmacologically similar to retatrutide) are increasingly advised by clinicians to:

• Maintain adequate dietary protein intake — general guidance from sports nutrition and dietetic sources suggests approximately 1.2–1.6 g per kg of body weight per day for those undertaking resistance exercise, though this should be individualised with a dietitian or clinician, particularly for older adults or those with kidney disease

• Engage in regular resistance exercise to preserve muscle tissue

• Consider evidence-based supplements such as creatine, under medical supervision

Whilst the specific combination of creatine and retatrutide has not been studied in clinical trials, the rationale for using creatine to support muscle preservation during weight loss is scientifically sound. Any supplementation strategy should be discussed with a healthcare professional familiar with the individual's full medical history.

Safety Considerations and When to Seek Medical Advice

Retatrutide's unapproved UK status means no quality or dosing guarantees exist outside trials; seek urgent medical attention for severe abdominal pain, biliary symptoms, or signs of pancreatitis, and report adverse reactions via the MHRA Yellow Card scheme.

Safety must remain the primary concern for anyone considering combining creatine with retatrutide, particularly given the latter's unapproved status in the UK. Obtaining retatrutide outside of a regulated clinical trial means there is no guarantee of product quality, accurate dosing, or appropriate medical oversight — all of which are essential safeguards. Medicines obtained from overseas or unregulated online sources may be counterfeit or incorrectly dosed.

From a creatine safety perspective, the supplement is generally well tolerated in healthy adults. However, the following groups should exercise particular caution and seek medical advice before use:

• Individuals with chronic kidney disease (CKD) or a history of renal impairment, as creatine increases creatinine excretion and may complicate renal monitoring

• Pregnant or breastfeeding individuals, due to insufficient safety data

• People taking nephrotoxic medications or other supplements that affect renal function

Note: creatine is not hepatically metabolised in the conventional sense, and routine caution in liver disease is not well established; however, individuals with significant liver conditions should seek individual medical advice.

With respect to retatrutide and the GLP-1 receptor agonist class more broadly, individuals should be aware of the following and seek prompt medical attention if they occur:

• Severe, persistent upper abdominal pain, with or without vomiting — this may indicate pancreatitis, a recognised risk with GLP-1-based therapies, and requires urgent medical assessment

• Biliary symptoms such as right upper abdominal pain, jaundice, or pale stools — gallbladder disease is a known class-associated risk

• Persistent nausea, vomiting, or abdominal pain that is not resolving

• Signs of dehydration (dark urine, dizziness, reduced urine output)

• Unexplained muscle weakness or cramps

• Symptoms of low blood glucose (shakiness, sweating, confusion) — this is most relevant in individuals also taking insulin or sulfonylureas, as retatrutide monotherapy carries a lower inherent risk of hypoglycaemia

Anyone who experiences a suspected adverse reaction or product quality concern should report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

NICE guidance on obesity management and pharmacotherapy is based on approved medicines. Any use of unapproved agents falls outside this framework, and individuals should be aware of the legal and health implications.

Key Points to Discuss With Your Doctor or Pharmacist

Disclose all supplements including creatine to your GP, pharmacist, or obesity medicine specialist, and ask about approved alternatives such as semaglutide (NICE TA875) or tirzepatide (NICE TA1026) that may be more appropriate.

Before combining creatine with retatrutide — or indeed before using retatrutide at all — a thorough conversation with a qualified healthcare professional is strongly recommended. In the UK, your GP, a registered pharmacist, or a specialist in endocrinology or obesity medicine are the most appropriate points of contact.

When speaking with your doctor or pharmacist, consider raising the following points:

• Disclose all supplements and medications you are currently taking, including creatine, protein powders, vitamins, and herbal products. This enables a complete interaction review.

• Ask about kidney function testing: A baseline renal function test (urea and electrolytes) is not routinely necessary for healthy adults starting creatine, but may be appropriate if you have risk factors such as pre-existing kidney disease, symptoms suggestive of renal impairment, or are taking other medicines that affect the kidneys. Your clinician can advise based on your individual circumstances. Bear in mind that creatine use can raise serum creatinine without indicating true kidney damage, so results should be interpreted in context.

• Discuss your weight-loss goals and muscle preservation strategy: A healthcare professional or registered dietitian can help you develop a safe, evidence-based plan that may include dietary protein targets, resistance exercise, and appropriate supplementation.

• Clarify the regulatory status of retatrutide and available alternatives: Your doctor can advise on whether approved alternatives may be more appropriate for your circumstances. Semaglutide (Wegovy) has MHRA authorisation and NICE approval for weight management in adults meeting specific criteria (NICE TA875). Tirzepatide (Mounjaro) has MHRA authorisation for type 2 diabetes and has received NICE approval for weight management in adults meeting specific criteria (NICE TA1026). Your clinician can confirm current eligibility criteria and whether either option is suitable for you.

• Report any side effects promptly: If you are already using retatrutide and experience new or worsening symptoms after starting creatine, inform your healthcare provider without delay. Suspected adverse reactions can also be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

In summary, whilst there is no established evidence of a harmful interaction between creatine and retatrutide, the absence of data is not the same as confirmed safety. Informed, supervised decision-making remains the cornerstone of responsible supplementation and pharmacotherapy.

Frequently Asked Questions